A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity

BACKGROUNDTo understand the features of a replicating vaccine that might drive potent and durable immune responses to transgene-encoded antigens, we tested a replication-competent adenovirus type 4 encoding influenza virus H5 HA (Ad4-H5-Vtn) administered as an oral capsule or via tonsillar swab or n...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of clinical investigation 2021-03, Vol.131 (5)
Main Authors:	Matsuda, Kenta, Migueles, Stephen A, Huang, Jinghe, Bolkhovitinov, Lyuba, Stuccio, Sarah, Griesman, Trevor, Pullano, Alyssa A, Kang, Byong H, Ishida, Elise, Zimmerman, Matthew, Kashyap, Neena, Martins, Kelly M, Stadlbauer, Daniel, Pederson, Jessica, Patamawenu, Andy, Wright, Nathaniel, Shofner, Tulley, Evans, Sean, Liang, C Jason, Candia, Julián, Biancotto, Angelique, Fantoni, Giovanna, Poole, April, Smith, Jon, Alexander, Jeff, Gurwith, Marc, Krammer, Florian, Connors, Mark
Format:	Article
Language:	eng
Subjects:	Adenoviruses Adenoviruses, Human - genetics Adenoviruses, Human - immunology Adenoviruses, Human - physiology Administration, Oral Adolescent Adult Antibodies, Neutralizing - blood Antibodies, Viral - blood Antigens, Viral - genetics Clinical Medicine Female Genetic Vectors Health aspects Hemagglutinin Glycoproteins, Influenza Virus - genetics Hemagglutinin Glycoproteins, Influenza Virus - immunology Humans Immune response Immunity, Cellular Immunity, Humoral Immunity, Mucosal Influenza A Virus, H5N1 Subtype - genetics Influenza A Virus, H5N1 Subtype - immunology Influenza vaccines Influenza Vaccines - administration & dosage Influenza Vaccines - genetics Influenza Vaccines - immunology Influenza, Human - immunology Influenza, Human - prevention & control Male Nasal Sprays Palatine Tonsil Testing Virus Replication Virus Shedding Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	BACKGROUNDTo understand the features of a replicating vaccine that might drive potent and durable immune responses to transgene-encoded antigens, we tested a replication-competent adenovirus type 4 encoding influenza virus H5 HA (Ad4-H5-Vtn) administered as an oral capsule or via tonsillar swab or nasal spray.METHODSViral shedding from the nose, mouth, and rectum was measured by PCR and culturing. H5-specific IgG and IgA antibodies were measured by bead array binding assays. Serum antibodies were measured by a pseudovirus entry inhibition, microneutralization, and HA inhibition assays.RESULTSAd4-H5-Vtn DNA was shed from most upper respiratory tract-immunized (URT-immunized) volunteers for 2 to 4 weeks, but cultured from only 60% of participants, with a median duration of 1 day. Ad4-H5-Vtn vaccination induced increases in H5-specific CD4+ and CD8+ T cells in the peripheral blood as well as increases in IgG and IgA in nasal, cervical, and rectal secretions. URT immunizations induced high levels of serum neutralizing antibodies (NAbs) against H5 that remained stable out to week 26. The duration of viral shedding correlated with the magnitude of the NAb response at week 26. Adverse events (AEs) were mild, and peak NAb titers were associated with overall AE frequency and duration. Serum NAb titers could be boosted to very high levels 2 to 5 years after Ad4-H5-Vtn vaccination with recombinant H5 or inactivated split H5N1 vaccine.CONCLUSIONReplicating Ad4 delivered to the URT caused prolonged exposure to antigen, drove durable systemic and mucosal immunity, and proved to be a promising platform for the induction of immunity against viral surface glycoprotein targets.TRIAL REGISTRATIONClinicalTrials.gov NCT01443936 and NCT01806909.FUNDINGIntramural and Extramural Research Programs of the NIAID, NIH (U19 AI109946) and the Centers of Excellence for Influenza Research and Surveillance (CEIRS), NIAID, NIH (contract HHSN272201400008C).
ISSN:	0021-9738 1558-8238